Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Naratriptan hydrochloride
Drug ID BADD_D01536
Description Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine attacks with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC02
DrugBank ID DB00952
KEGG ID D00674
MeSH ID C106783
PubChem ID 60875
TTD Drug ID D0T3KI
NDC Product Code 62147-0195; 55111-085; 53873-056; 52482-011; 53873-055
UNII 10X8X4P12Z
Synonyms naratriptan | N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide | GR 85548A | naratriptan hydrochloride | N-methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride | 1H-indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride | Naramig | Amerge | Colatan
Chemical Information
Molecular Formula C17H26ClN3O2S
CAS Registry Number 143388-64-1
SMILES CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash pruritic23.03.13.030--Not Available
Red blood cell count13.01.05.020--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Rhinitis22.07.03.006; 11.01.13.004--
Rhinitis allergic10.01.04.003; 22.04.04.003--
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Serotonin syndrome12.03.01.041; 17.05.02.004; 15.05.04.016--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin exfoliation23.03.07.003--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.011--Not Available
Swelling08.01.03.015--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tracheitis11.01.13.007; 22.07.03.009--
Transient ischaemic attack17.08.04.001; 24.04.06.005--
Tremor17.01.06.002--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
Varicose vein24.10.04.001--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Vomiting07.01.07.003--
White blood cell count increased13.01.06.013--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages